A drug developed by Biogen Inc. and Eisai Co. has achieved a first in Alzheimer's research: In a large, late-stage trial, lecanemab slowed down the cognitive decline in people with early disease. The therapy's effect was modest. But given the litany of ...
VIEW MORE : https://bit.ly/1breakingnews
